Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis

被引:0
|
作者
Bastos, Mayara Lisboa [1 ,2 ,3 ]
Oxlade, Olivia [3 ]
Campbell, Jonathon R. [2 ,3 ]
Faerstein, Eduardo [1 ]
Menzies, Dick [2 ,3 ]
Trajman, Anete [1 ,3 ,4 ,5 ]
机构
[1] Univ Estado Rio De Janeiro, Social Med Inst, Rio De Janeiro, Brazil
[2] McGill Univ, Ctr Outcomes Res & Evaluat, Resp Epidemiol & Clin Res Unit, Res Inst,Hlth Ctr, Montreal, PQ, Canada
[3] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[4] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil
[5] Rua Macedo Sobrinho 74-203, BR-22271080 Rio De Janeiro, Brazil
来源
基金
加拿大健康研究院;
关键词
Brazil; Tuberculosis; Latent tuberculosis; Cascade-of-care; cost-effectiveness; budget impact; tuberculosis preventive therapy;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background In Brazil, investigation and treatment of tuberculosis infection (TBI) in households contacts (HHC) of TB patients is not a priority. We estimated the cost-effectiveness and budget-impact of scaling-up an enhanced HHC management in Brazil.Methods We conceptualized a cascade-of-care that captures how HHC of tuberculosis patients are investigated in Brazil (status quo) and two enhanced strategies for management of HHC focusing on: (1) only tuberculosis disease (TBD) detection and, (2) TBD and TBI detection and treatment. Effectiveness was the number of HHC diagnosed with TBD and completing TBI treatment. Proportions in the cascades-of-care were derived from a meta-analysis. Health-system costs (2019 US$) were based on literature and official data from Brazil. The impact of enhanced strat-egies was extrapolated using reported data from 2019.Findings With the status quo, 0 (95% uncertainty interval: 0-1) HHC are diagnosed with TBD and 2 (0-16) complete TBI treatment. With strategy(1), an additional 15 (3-45) HHC would be diagnosed with TBD at a cost of US$346 each. With strategy(2), 81 (19-226) additional HHC would complete TBI treatment at a cost of US$84 each. A com-bined strategy, implemented nationally to enhance TBD detection and TBI treatment would result in an additional 9,711 (845-28,693) TBD being detected, and 51,277 (12,028-143,495) more HHC completing TBI treatment each year, utilizing 10.9% and 11.6% of the annual national tuberculosis program budget, respectively. Interpretation Enhanced detection and treatment of TBD and TBI among HHC in Brazil can be achieved at a national level using current tools at reasonable cost.Copyright (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) The 2022;8:
引用
收藏
页数:12
相关论文
共 50 条
  • [21] A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIDAXOMICIN FOR TREATING CLOSTRIDIUM DIFFICILE PATIENTS IN GERMANY
    Watt, M.
    McCrea, C.
    Johal, S.
    Posnett, J.
    Nazir, J.
    VALUE IN HEALTH, 2015, 18 (03) : A233 - A233
  • [22] Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis
    Vadagam, Pratyusha
    Kamal, Khalid M.
    Covvey, Jordan R.
    Giannetti, Vincent
    Mukherjee, Kumar
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (10): : 987 - +
  • [23] Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors
    Cortesi, Paolo Angelo
    Castaman, Giancarlo
    Trifiro, Gianluca
    Creazzola, Simona Serao
    Improta, Giovanni
    Mazzaglia, Giampiero
    Molinari, Angelo Claudio
    Mantovani, Lorenzo Giovanni
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 216 - 228
  • [24] BUDGET IMPACT AND COST-EFFECTIVENESS OF SUGAMMADEX IN THE REVERSAL OF PATIENTS WITH NEUROMUSCULAR BLOCK
    Sabater, F. J.
    Aguilera, L.
    Canet, J.
    Echevarria, M.
    Lora-Tamayo, J., I
    Poveda, J. L.
    Sabate, A.
    Lopez-Belmonte, J. L.
    VALUE IN HEALTH, 2009, 12 (07) : A366 - A366
  • [25] Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis
    Basu, Sanjay
    Wagner, Ryan G.
    Sewpaul, Ronel
    Reddy, Priscilla
    Davies, Justine
    LANCET GLOBAL HEALTH, 2019, 7 (02): : E270 - E280
  • [26] Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
    Cortesi, Paolo Angelo
    Antonazzo, Ippazio Cosimo
    Gasperini, Claudio
    Nica, Mihaela
    Ritrovato, Daniela
    Mantovani, Lorenzo Giovanni
    PLOS ONE, 2022, 17 (03):
  • [27] Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis
    Goudarzi, Zahra
    Lotfi, Farhad
    Shahtaheri, Rahil sadat
    Moradi, Nasrin
    Taghizadeh, Mohsen
    Keshavarz, Khosro
    BMC MEDICINE, 2025, 23 (01):
  • [28] Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion
    Sendi, Pedram
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    HEALTHCARE, 2021, 9 (11)
  • [29] The ethics of aggregation in cost-effectiveness analysis or, "on books, bookshelves, and budget impact"
    Charlton, Victoria
    FRONTIERS IN HEALTH SERVICES, 2022, 2
  • [30] A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis
    Hassan, Nor Zam Azihan Mohd
    Razali, Asmah
    Kunusagaran, Mohd Shaiful Jefri Mohd Nor Sham
    Aminuddin, Farhana
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2022, 29